Welcome to our dedicated page for CLVS news (Ticker: CLVS), a resource for investors and traders seeking the latest updates and insights on CLVS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLVS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLVS's position in the market.
Clovis Oncology (NASDAQ: CLVS) has submitted two Investigational New Drug (IND) applications to the FDA for FAP-2286, a leading compound in its peptide-targeted radionuclide therapy program. After FDA clearance, the company will initiate a Phase 1/2 clinical trial to assess the dose and tolerability of the therapeutic agent 177Lu-FAP-2286, targeting fibroblast activation protein (FAP) in various solid tumors. This development marks a significant milestone in Clovis's efforts to establish a foothold in the emerging field of targeted radiopharmaceuticals.
Clovis Oncology, Inc. (NASDAQ: CLVS) announced positive topline data from the Phase 3 ARIEL4 study of Rubraca for treating relapsed ovarian cancer with BRCA mutations. The trial met its primary endpoint of improved investigator-assessed progression-free survival (InvPFS) compared to chemotherapy, showing a median of 7.4 months for Rubraca versus 5.7 months for chemotherapy. A total of 349 women participated, and statistical significance was established with a hazard ratio of 0.639 (p=0.0010). The study reinforces Rubraca as a viable treatment option for advanced ovarian cancer patients.
Clovis Oncology (NASDAQ: CLVS) announced that a Holder has opted to purchase an additional $7.5 million of its 4.50% Convertible Senior Notes due 2024, increasing the total to $57.5 million. The settlement is expected on November 27, 2020. Proceeds will be utilized for general corporate purposes, including debt repayment, marketing expenses for Rubraca®, and development funding. The New 2024 Notes and convertible shares are offered under exemptions from registration and are not registered under the Securities Act.
Clovis Oncology (Nasdaq: CLVS) announced a pre-recorded fireside chat featuring CEO Patrick J. Mahaffy, available for replay during the Piper Sandler 32nd Annual Healthcare Conference from November 30 to December 3, 2020. The presentation will be accessible on the Company's investor relations website starting November 23, 2020, at 10:00 a.m. ET. Recorded on November 18, 2020, the session will remain available for 30 days. Clovis focuses on developing innovative anti-cancer agents and associated diagnostic tools, targeting specific cancer populations.
Clovis Oncology (NASDAQ:CLVS) reported third-quarter 2020 results, with Rubraca revenues slightly up to $38.8 million despite COVID-19 challenges. The company is shifting to a hybrid commercial strategy focused on digital interactions to boost sales. R&D expenses decreased to $62.9 million, and overall cash burn fell by 25% to $37.7 million in Q3. Clovis anticipates Q4 revenues between $38 million and $40 million and expects sufficient cash to fund its operations into early 2023. Upcoming milestones include clinical data from ongoing studies and a possible sNDA filing in 2021.
Clovis Oncology (NASDAQ: CLVS) announced an agreement on November 4, 2020, to exchange $64.8 million of its 4.50% Convertible Senior Notes due 2024 for common stock, potentially issuing up to 15.7 million shares. They will also issue $50 million of New Convertible Senior Notes, with a 4.50% interest rate, maturing in 2024. The proceeds will be used for general corporate purposes, including debt repayment and development programs. The first issuance of shares is expected on November 6, 2020, with final calculations set by November 17, 2020.
Clovis Oncology (NASDAQ: CLVS) will release its Q3 2020 financial results on November 5, 2020, before U.S. markets open. A conference call will follow at 8:30 a.m. ET to discuss the results in detail. Investors can access the live webcast via the company's website, with an archived replay available for 30 days. Clovis focuses on developing and commercializing innovative anti-cancer agents and diagnostic tools targeting specific cancer subsets.